NanoViricides Inc. (NNVC)

[Rawnoc]

PATRICK COX: We ought to talk about the income model for a small bio-tech firm, and that is I think long before this drug appears in Walgreens, one of the big Pharm players is going to be approaching NanoViricides to license this technology. They are going to have income before it ever hits the shelves.

EUGENE SEYMOUR: Oh absolutely. I anticipate income as early as next year. If I come back from Africa and I have the results that I am anticipating, I am certain that every Pharma company that is in the HIV business is going to want to do a licensing deal because otherwise they are going to have their lunch eaten. HIV is projected to be a 21 billion dollar worldwide market in the next three years. There is one company that does 6 billion a year now. They would lose their franchise if something came out of left field, like us, and threatened their control over the drug.

~~October 2010

"All of the major pharmas have approached me, but they said we're not going to come back until you do Phase 2a trials"
http://www.nbtequitiesresearch.com/video/nbt-nano-viricides-2a

~~November 2013